

10 July 2026

Additional Australian patent grant strengthens proprietary IP portfolio

- **Australian patent granted covering proprietary crystalline forms of psilocin, strengthening Entropy's intellectual property portfolio**
- **Patent provides composition-of-matter protection over multiple novel psilocin salt and cocrystal forms with improved stability and solubility**
- **Claims also cover manufacturing methods, pharmaceutical formulations and therapeutic applications across a range of neuropsychiatric disorders**
- **Patent complements Entropy's existing international patent strategy, supporting long-term global commercialisation opportunities**
- **Australian patent remains in force until September 2043**

Melbourne, Australia – Entropy Neurodynamics Limited ('**Entropy Neurodynamics**' or the '**Company**') (**ASX: ENP**), a clinical-stage biotechnology company, is pleased that the Australian Patent Office has granted Australian Standard Patent No. 2023343417, titled "Psilocin Crystalline Forms", further strengthening the Company's intellectual property portfolio supporting its proprietary psilocin platform.

The granted patent provides composition-of-matter protection over multiple proprietary crystalline forms of psilocin, including novel salt and cocrystal forms designed to improve the stability, solubility and pharmaceutical properties of psilocin.

The patent also includes claims covering methods of manufacture, pharmaceutical formulations and therapeutic use across a broad range of 5-HT_{2A} receptor-mediated disorders.

The patent further strengthens the Company's intellectual property portfolio supporting the development of next-generation and innovative psilocin-based therapeutics, including intravenous, oral and other precision-controlled delivery approaches.

The Australian patent complements the Company's broader international intellectual property strategy, with the underlying invention also protected through its international Patent Cooperation Treaty (PCT) application, supporting future patent prosecution across key global markets.

The patent has a 20-year term from 12 September 2023 and, subject to payment of applicable renewal fees, and is expected to remain in place until September 2043.



Management commentary:

CEO, Mr Jason Carroll said: *"Protecting our proprietary intellectual property is a core component of Entropy's long-term strategy and key to advancing as our precision-controlled platform."*

This patent strengthens our composition-of-matter protection around novel psilocin crystalline forms that have the potential to deliver important pharmaceutical advantages, including enhanced stability and solubility, key components to ongoing drug development and commercialisation.

Combined with our broader international patent strategy, this grant further reinforces the value of our platform and supports future commercialisation opportunities across multiple therapeutic indications."

This announcement has been authorised by the Board of Entropy Neurodynamics Limited.

– ENDS –

INVESTOR & MEDIA CONTACT

Jason Carroll

Chief Executive Officer
Entropy Neurodynamics Limited
jcarroll@tryptherapeutics.com

Henry Jordan

Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Entropy Neurodynamics Limited

Entropy Neurodynamics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. Results from each of these trials demonstrated the clinical benefits of psychedelic therapy and will be used to further enhance the development of TRP-8803.

Register for updates

The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done via the following steps:

- *Go to investor.automic.com.au*
- *If you're an existing user, log in with your username and password*
- *If you're a new user, click 'register', select 'Entropy Neurodynamics Limited'. Enter your Holding*

Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.

- Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and select 'electronic only'.

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimen used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Entropy Neurodynamics as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of the Company's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Entropy Neurodynamics; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.